Revance, Velocity + MedPharmics, Arsenal, SpringWorks

A critical aesthetics approval, site network buy-up, a very normal oncology biotech, and a busy week for one company.  Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesRevanceVelocity +…

Novo + Forma, Sanofi, Boehringer Ingelheim, Arcturus

A $1.1B acquisition, two FDA approvals, and grants for mRNA vaccines.  Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesNovo + FormaSanofiBoehringer IngelheimArcturus About the ShowLife Science Today is…

Alcon + Aerie, Novartis + Sandoz, Labcorp + RWJBH

Ophthalmology acquisitions, following the pharma trends, and a move in healthcare that is not technology related.  Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesAlcon + AerieNovartis + SandozLabcorp…

Pfizer, Cerevel, Abbott, AstaZeneca + Daiichi Sankyo

Spending that COVID money, brain money, Irish money, and another oncology approval.  Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesPfizerCerevelAbbottAstaZeneca + Daiichi SankyoAbout the ShowLife Science Today is…

Zymergen + Ginkgo, Cassava, Teva

This week, we take a break from stories of raising capital, mergers, and FDA approvals to look at the dark side of our industry. What…

Vertex + ViaCyte, Theravance, Merck + Orion, Pliant, Qiming

Cell therapy acquisition, royalties sold, biobucks-like deal, successful raise, and Chinese Venture Capital Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesVertex + ViaCyteTheravance BiopharmaMerck + OrionPliant Therapeutics QimingAbout…